Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis

Journal of Neurology

Volumn 260, Issue 8, 2013, Pages 2163-2165

  Catzola, Valentina ^a   Battaglia, Alessandra ^a   Buzzonetti, Alexia ^a   Fossati, Marco ^a   Scuderi, Flavia ^a   Fattorossi, Andrea ^a   Evoli, Amelia ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; INTERLEUKIN 2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR FOXP3;

ADOLESCENT; ADULT; B LYMPHOCYTE; CASE REPORT; CD4+ CD25+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL EXPANSION; DISEASE SEVERITY; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MULTIPLE CYCLE TREATMENT; MYASTHENIA GRAVIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RELAPSE; T LYMPHOCYTE; TREATMENT DURATION;

EID: 84881536228     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6987-y     Document Type: Letter

References (14)

1. Townsend MJ, Monroe JG, Chan AC (2010) B-cell targeted therapies in human autoimmune diseases: an update perspective. Immunol Rev 237:264-283
2. Stasi R, Cooper N, Del Poeta G et al (2008) Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112:1147-1150
3. Sfikakis PP, Souliotis VL, Fragiadaki KG et al (2007) Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 123:66-73
4. + T regulatory cells in myasthenia gravis: effect of immunosuppressive treatment. Immunology 116:134-141
5. Thiruppathi M, Rowin J, Li Jiang Q et al (2012) Functional defect in regulatory T cells in myasthenia gravis. Ann NY Acad Sci 1274:68-76
6. Meriggioli MN, Sanders DB (2009) Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol 8:475-490
7. Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM (2011) Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 4:259-266
8. Díaz-Manera J, Martínez-Hernández E, Querol L et al (2012) Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78:189-193
9. Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55:16-23
10. Battaglia A, Buzzonetti A, Baranello C et al (2012) IL-21 synergises with IL-2 to enhance TCR-β-induced human T cell proliferation and counteracts IL-2/TGF-β induced regulatory T cell development. Immunology 139:109-120
11. Fattorossi A, Battaglia A, Ferrandina G et al (2004) Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Cancer 100:1418-1428
12. Khosroshahi A, Bloch DB, Deshpande V, Stone JH (2010) Rituximab therapy leads to rapid decline of serum IgG4 levels and prompts clinical improvement in IgG4-related systemic disease. Arthritis Rheum 62:1755-1762
13. + T cell immunity. Nat Rev Immunol 10:236-247
14. Baran J, Kowalczyk D, Ozóg M, Zembala M (2001) Three-color flow cytometry detection of intracellular cytokines in peripheral blood mononuclear cells: comparative analysis of phorbol myristate acetate-ionomycin and phytohemagglutinin stimulation. Clin Diagn Lab Immunol 8:303-313